Moleculin Biotech
MBRX
MBRX
21 hedge funds and large institutions have $1.33M invested in Moleculin Biotech in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less first-time investments, than exits
New positions opened: | Existing positions closed:
54% less capital invested
Capital invested by funds: $2.91M → $1.33M (-$1.58M)
Holders
21
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$30.8K | |
| 2 | +$19.5K | |
| 3 | +$19K | |
| 4 |
PJSIMP
P.J. Schmidt Investment Management (PJS)
Cedarburg,
Wisconsin
|
+$19K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.18K |
Top Sellers
| 1 | -$410K | |
| 2 | -$36.2K | |
| 3 | -$30.6K | |
| 4 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$23.4K |
| 5 |
VF
Virtu Financial
New York
|
-$16K |